NRXP

NRX Pharmaceuticals, Inc. NRXP

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,735 of 2,925

Why it scores 21Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$1.10M

Quarter to Jun 30

Net income

$-16.52M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$47.59M total
B Group, Inc.
$16.74M+36.4%
VANGUARD CAPITAL MANAGEMENT LLC
$6.62M+39.5%
AMERIPRISE FINANCIAL INC
$3.80MNew
BALYASNY ASSET MANAGEMENT L.P.
$3.66MNew
CITADEL ADVISORS LLC
$2.78MNew
AdvisorShares Investments LLC
$2.70M+56.7%
COMMONWEALTH EQUITY SERVICES, LLC
$1.86M+14.3%
UBS Group AG
$1.73M+1576.4%
GEODE CAPITAL MANAGEMENT, LLC
$1.29M+1.5%
BlackRock, Inc.
$901.7K+122.7%
MARSHALL WACE, LLP
$795.8KNew
VANGUARD FIDUCIARY TRUST CO
$747.3K+7.7%
JANE STREET GROUP, LLC
$486.8K+169.6%
Bleakley Financial Group, LLC
$479.4K0.0%
STATE STREET CORP
$474.8K+33.5%
HRT FINANCIAL LP
$411.0KNew
NORTHERN TRUST CORP
$257.5K+44.8%
Chicago Partners Investment Group LLC
$190.7K+34.5%
Quadrature Capital Ltd
$178.3KNew
One Wealth Management Investment & Advisory Services, LLC
$177.1K0.0%
MORGAN STANLEY
$167.3K+307.9%
RENAISSANCE TECHNOLOGIES LLC
$157.9KNew
Global Retirement Partners, LLC
$136.2K--
TWO SIGMA INVESTMENTS, LP
$108.1KNew
TRUIST FINANCIAL CORP
$81.8KNew
See all 47 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/NRXP

Earnings Per Share

13fpro.ai/company/NRXP

Loading ratio trend…

NRXP key financials by period

Reported revenue, net income and operating margin by fiscal year, from NRX Pharmaceuticals, Inc.'s annual filings on SEC EDGAR.

NRX Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$1.2M$-28.6M—
Source: NRXP filings on SEC EDGAR →

NRXP insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About NRX Pharmaceuticals, Inc. (NRXP): stock profile, AI score and financials

NRX Pharmaceuticals, Inc. (NRXP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NRXP at 21.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,735 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), NRX Pharmaceuticals, Inc. reports quarterly revenue of $1.1M, net income of $-16.5M. Top institutional holders of NRXP by reported 13-F value include B Group, VANGUARD CAPITAL MANAGEMENT, AMERIPRISE FINANCIAL, based on the most recent SEC filings. NRXP trades on the Nasdaq exchange and files with the SEC under CIK 1719406. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRXP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NRX Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1719406 →